Ai-Ris, founded with the mission to revolutionize disease detection, offers automated retinal examinations for primary care. Their core product is a portable headset that employs machine learning algorithms to screen for diseases such as diabetic retinopathy, AMD, and Alzheimer's Disease. This innovative system allows general practitioners to conduct retinal exams without the need for pupil dilation or specialist intervention, making early and precise detection more accessible.
Notable affiliated individuals and investors include experts in machine learning and healthcare technology, though specific names are not disclosed. Ai-Ris has achieved significant milestones, including securing U.S. patents for their technology and forming trusted partnerships within the medical community. Their impact is profound, addressing the leading cause of preventable blindness in adults and potentially transforming early disease detection on a global scale.
